Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy

Lignende værker

• Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
  af: Saida, Yu, et al.
  Udgivet: (2019)
• Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC
  af: Gal, Omer, et al.
  Udgivet: (2020)
• Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC
  af: Landi, Lorenza, et al.
  Udgivet: (2016)
• Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs)
  af: Mountzios, Giannis
  Udgivet: (2018)
• The emerging treatment landscape of advanced non-small cell lung cancer
  af: Economopoulou, Panagiota, et al.
  Udgivet: (2018)